370 related articles for article (PubMed ID: 32117299)
1. The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass.
Deveuve Q; Lajoie L; Barrault B; Thibault G
Front Immunol; 2020; 11():168. PubMed ID: 32117299
[TBL] [Abstract][Full Text] [Related]
2. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
[TBL] [Abstract][Full Text] [Related]
3. Structural determinants of unique properties of human IgG4-Fc.
Davies AM; Rispens T; Ooijevaar-de Heer P; Gould HJ; Jefferis R; Aalberse RC; Sutton BJ
J Mol Biol; 2014 Feb; 426(3):630-44. PubMed ID: 24211234
[TBL] [Abstract][Full Text] [Related]
4. A hingeless Fc fusion system for site-specific cleavage by IdeS.
Novarra S; Grinberg L; Rickert KW; Barnes A; Wilson S; Baca M
MAbs; 2016; 8(6):1118-25. PubMed ID: 27210548
[TBL] [Abstract][Full Text] [Related]
5. Anti-Hinge Antibodies Recognize IgG Subclass- and Protease-Restricted Neoepitopes.
Falkenburg WJ; van Schaardenburg D; Ooijevaar-de Heer P; Tsang-A-Sjoe MW; Bultink IE; Voskuyl AE; Bentlage AE; Vidarsson G; Wolbink G; Rispens T
J Immunol; 2017 Jan; 198(1):82-93. PubMed ID: 27864476
[TBL] [Abstract][Full Text] [Related]
6. Recombinant thyroid peroxidase-specific Fab converted to immunoglobulin G (IgG) molecules: evidence for thyroid cell damage by IgG1, but not IgG4, autoantibodies.
Guo J; Jaume JC; Rapoport B; McLachlan SM
J Clin Endocrinol Metab; 1997 Mar; 82(3):925-31. PubMed ID: 9062508
[TBL] [Abstract][Full Text] [Related]
7. Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo.
Hsiao HC; Fan X; Jordan RE; Zhang N; An Z
Breast Cancer Res; 2018 Jun; 20(1):43. PubMed ID: 29859099
[TBL] [Abstract][Full Text] [Related]
8. [The hinge region of therapeutic antibodies: major importance of a short sequence].
Deveuve Q; Gouilleux-Gruart V; Thibault G; Lajoie L
Med Sci (Paris); 2019 Dec; 35(12):1098-1105. PubMed ID: 31903923
[TBL] [Abstract][Full Text] [Related]
9. A novel therapeutic strategy to rescue the immune effector function of proteolytically inactivated cancer therapeutic antibodies.
Fan X; Brezski RJ; Deng H; Dhupkar PM; Shi Y; Gonzalez A; Zhang S; Rycyzyn M; Strohl WR; Jordan RE; Zhang N; An Z
Mol Cancer Ther; 2015 Mar; 14(3):681-91. PubMed ID: 25552368
[TBL] [Abstract][Full Text] [Related]
10. Evading pre-existing anti-hinge antibody binding by hinge engineering.
Kim HS; Kim I; Zheng L; Vernes JM; Meng YG; Spiess C
MAbs; 2016; 8(8):1536-1547. PubMed ID: 27606571
[TBL] [Abstract][Full Text] [Related]
11. The deficient cleavage of M protein-bound IgG by IdeS: insight into the escape of Streptococcus pyogenes from antibody-mediated immunity.
Su YF; Chuang WJ; Wang SM; Chen WY; Chiang-Ni C; Lin YS; Wu JJ; Liu CC
Mol Immunol; 2011 Oct; 49(1-2):134-42. PubMed ID: 21925735
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD20 rituximab IgG1, IgG3, and IgG4 but not IgG2 subclass trigger Ca
Freitas Monteiro M; Papaserafeim M; Réal A; Puga Yung GL; Seebach JD
J Leukoc Biol; 2020 Oct; 108(4):1409-1423. PubMed ID: 32620047
[TBL] [Abstract][Full Text] [Related]
13. Cleavage of anti-PF4/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia.
Kizlik-Masson C; Deveuve Q; Zhou Y; Vayne C; Thibault G; McKenzie SE; Pouplard C; Loyau S; Gruel Y; Rollin J
Blood; 2019 May; 133(22):2427-2435. PubMed ID: 30917957
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge.
Brezski RJ; Vafa O; Petrone D; Tam SH; Powers G; Ryan MH; Luongo JL; Oberholtzer A; Knight DM; Jordan RE
Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17864-9. PubMed ID: 19815504
[TBL] [Abstract][Full Text] [Related]
15. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
16. IgG2m4, an engineered antibody isotype with reduced Fc function.
An Z; Forrest G; Moore R; Cukan M; Haytko P; Huang L; Vitelli S; Zhao JZ; Lu P; Hua J; Gibson CR; Harvey BR; Montgomery D; Zaller D; Wang F; Strohl W
MAbs; 2009; 1(6):572-9. PubMed ID: 20073128
[TBL] [Abstract][Full Text] [Related]
17. IgG4 antibodies from patients with asymptomatic bancroftian filariasis inhibit the binding of IgG1 and IgG2 to C1q in a Fc-Fc-dependent mechanism.
Prodjinotho UF; Hoerauf A; Adjobimey T
Parasitol Res; 2019 Oct; 118(10):2957-2968. PubMed ID: 31485865
[TBL] [Abstract][Full Text] [Related]
18. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc.
Idusogie EE; Presta LG; Gazzano-Santoro H; Totpal K; Wong PY; Ultsch M; Meng YG; Mulkerrin MG
J Immunol; 2000 Apr; 164(8):4178-84. PubMed ID: 10754313
[TBL] [Abstract][Full Text] [Related]
19. Fc-Fusion Drugs Have FcγR/C1q Binding and Signaling Properties That May Affect Their Immunogenicity.
Lagassé HAD; Hengel H; Golding B; Sauna ZE
AAPS J; 2019 May; 21(4):62. PubMed ID: 31062128
[TBL] [Abstract][Full Text] [Related]
20. Clusterin binds by a multivalent mechanism to the Fc and Fab regions of IgG.
Wilson MR; Easterbrook-Smith SB
Biochim Biophys Acta; 1992 Oct; 1159(3):319-26. PubMed ID: 1390937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
